Camurus' FDA accepts CAM2029 NDA resubmission for acromegaly, sets December decision date
MAXONA Pharmaceuticals' Phase 2 clinical trial IND application for MAX-001 cleared by US FDA
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC